Roche Wins FDA Approval for Advanced Breast Cancer Pill Wilserdly
The U.S. Food and Drug Administration approved Roche’s breast cancer pill Wilserdly, also known as giredestrant, on November 16. The decision covers its use with everolimus in adults with certain advanced breast cancers carrying an ESR1 mutation. Eligible patients must have estrogen receptor-positive, HER2-negative disease that returned or progressed following specified hormone-based treatments.
The approval follows a late-stage trial that included 207 patients with ESR1-mutated tumors. The combination reduced the risk of disease progression or death by 62% compared with another hormone treatment plus everolimus. Median time without cancer progression reached 10 months, versus 5.5 months for the comparison group. The FDA also authorized a companion diagnostic test to identify eligible patients.
Meanwhile, Roche plans to price the treatment at $22,500 monthly, according to RBC Capital Markets analyst Trung Huynh. That equals about $270,000 annually, broadly matching Eli Lilly’s Inluriyo. Lilly’s medicine, used with Verzenio, already offers an oral treatment for the same breast cancer subtype after earlier hormone therapy.
Why it matters
The approval gives Roche another commercial oncology product while increasing competition in oral breast cancer treatments.


